Adeno-Associated Virus Gene Therapy for Diabetes and Obesity
Posted Nov 15 2012 7:00pm
Description of Invention: This invention is directed to adeno-associated virus (AAV) vector delivery of exendin-4 (Ex-4) to salivary glands as treatment for diabetes and obesity. Ex-4 is a potent and long-acting agonist of the receptor for glucagon-like peptide 1 (GLP-1). Scientists at NIDCR have shown that AAV-mediated delivery of Ex-4 resulted in improved glucose homeostasis and weight profile in two rat models of obesity and type 2 diabetes. Further, AAV-mediated delivery of Ex-4 to rat salivary glands resulted in localized and sustained expression of Ex-4 that was biologically active and well tolerated.
AAV-mediated delivery of Ex-4 is superior to administering GLP-1 analogs in that AAV-Ex-4 expression is more stable and longer acting. Like GLP-1 analogs, Ex-4 expression also potentially provides beneficial effects like reduced hypoglycemia, appetite suppression, and potential weight loss.
Applications: Therapy for diabetes or obesity.
Potential for potent glucose homeostasis therapy with longer duration than current drugs.
More convenient than daily or weekly injections.
In vitro data available
In vivo data available (animal)
Inventors: John A Chiorini (NIDCR) Giovanni Di Pasquale (NIDCR) Edward Mannucci (Careggi Teaching Hospital)
Collaborative Research Opportunity: The NIDCR is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize treatment of diabetes by expression NGF-extendin 4 protein. For collaboration opportunities, please contact David Bradley, Ph.D. at 301-402-9242 or email@example.com .